WHEN BIOCHEMICAL FAILURE DOES NOT MEAN CANCER RECURRENCE IN MEN TREATED BY EXTERNAL BEAM RADIOTHERAPY AND ADJUVANT HORMONES FOR INTERMEDIATE RISK PROSTATE CANCER

被引：0
|
作者：
Busca, Ionut [1 ]
Aljawi, Ghufran [1 ]
MacRae, Robert [1 ]
Eapon, Libni [1 ]
机构：
[1] Univ Ottawa, Ottawa, ON, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2019年 / 139卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [31] The Importance of an Exponential PSA Decline After External Beam Radiotherapy For Intermediate Risk Prostate Cancer
    Delouya, G.
    Kaufman, G.
    Sylvestre, M.
    Nguyen, T.
    Bahary, J.
    Taussky, D.
    Despres, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S444 - S444
  • [32] Trial Participation is Not Associated with Better Biochemical Recurrence-free Survival in a Large Cohort of External Beam Radiotherapy-Treated Intermediate- and High-Risk Prostate Cancer Patients
    Flammia, R. S.
    Lavigne, D.
    Tian, Z.
    Saad, F.
    Anceschi, U.
    Gallucci, M.
    Leonardo, C.
    Preisser, F.
    Mandel, P.
    Chun, F. K. H.
    Karakiewicz, P., I
    Delouya, G.
    Taussky, D.
    Hoeh, B.
    CLINICAL ONCOLOGY, 2023, 35 (01) : E77 - E84
  • [33] Use of statins and the risk of prostate cancer biochemical recurrence in men treated with radical prostatectomy.
    Trapp, Luke
    Helenowski, Irene B.
    Gurley, Michael
    Leikin, Robin
    Catalona, William
    Jovanovic, Borko
    Kuzel, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Quality of life in intermediate or high risk prostate cancer patients treated by external beam radiotherapy and brachytherapy with or without androgen deprivation
    Lacorte-Pi, T. M.
    Guix-Melcior, B.
    Guedea-Edo, F.
    PSYCHO-ONCOLOGY, 2006, 15 (02) : S296 - S297
  • [35] Intermediate Risk Prostate Cancer Treated with Hypofractionated External Beam Radiotherapy without Androgen Deprivation: Preliminary Results and Toxicity Analysis
    Dal Pra, A. L.
    Faria, S.
    Cury, F.
    David, M.
    Duclos, M.
    Shenouda, G.
    Souhami, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S189 - S189
  • [36] Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone
    Andruska, Neal
    Fischer-Valuck, Benjamin W.
    Carmona, Ruben
    Agabalogun, Temitope
    Brenneman, Randall J.
    Gay, Hiram A.
    Michalski, Jeff M.
    Baumann, Brian C.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (04): : 343 - +
  • [37] Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy
    Ong, Wee Loon
    Evans, Sue M.
    Millar, Jeremy L.
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2018, 62 (02) : 256 - 261
  • [38] Excellent biochemical control of subgroup of high risk prostate cancer treated with conformal radiotherapy and one year intermediate adjuvant androgen deprivation
    Padovani, L.
    Lechevallier, E.
    Bastide, C.
    Badinand, D.
    Rossi, D.
    Thirion, X.
    Coulange, C.
    Cowen, D.
    Muracciole, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S375 - S376
  • [39] Men with intermediate risk prostate cancer with a history of transurethral resection of prostate (TURP) have a higher risk of biochemical failure
    D'Ambrosio, DJ
    Buyyounouski, MK
    Horwitz, EM
    Feigenberg, SJ
    Ruth, K
    Pollack, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S311 - S311
  • [40] Rates of biochemical recurrence, metastasis and death in men managed on active surveillance for intermediate risk prostate cancer
    Amin, Amer
    Blazevski, Alexandar
    Stricker, Phillip
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 113 - 113
12345